drug_type
RELEVANT_DRUG
intervention_type
Genetically modified cellular therapy (CAR T cells)
drug_description
Autologous (or donor-derived) T cells genetically modified to express an anti-CD19 chimeric antigen receptor that binds CD19 on B-lineage cells and activates T-cell cytotoxicity to eliminate CD19+ leukemic blasts; induces B-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous or donor-derived T cells are engineered to express an anti‑CD19 chimeric antigen receptor. Binding to CD19 on B‑lineage cells activates CAR signaling (CD3ζ with costimulatory domains), driving T‑cell proliferation, cytokine release, and perforin/granzyme‑mediated cytotoxicity to eradicate CD19+ leukemic blasts, resulting in on‑target B‑cell aplasia.
drug_name
CAR-T-19 cell injection
nct_id_drug_ref
NCT06179524